RE:Game Changing? boazklinhorn, "One has to ask oneself what is a so called "game changing technology" worth? For years Gilles has been using that term to describe the PGX. Game changing. Well now we know that for Gilles, if his personal future is at risk what was once game changing can be sold . Cheap. 50% of the game changing PGX technology is being sold from under CZO shareholders who have been faithful and believed for years in the much hyped potential of the PGX. Sold for about 20 Miillon Canadian dollars."
H.C. Wainwright's November 13, 2023 target price for AEZS's shares was US$15. Based on 4.86 million shares that target price represents about C$100 million in market cap. H.C. Wainwright's target price was also set before the recent 19% up move in the S&P Biotech ETF as interest rate concerns ease and we may be in a new bull market for biotech.
Gilles may have scooped up valuable and complementary assets at the bottom of the biotech market. Gilles is also in the catbird seat as AEZS has been in talks for relicensing its growth hormone deficiency test for North America and Gilles should have a good understanding of the deals being discussed as the pediatric clinical trial is also expected to be concluding. The product has also been launching in several counties in Europe, etc., for the adult market and Gilles should have a good idea how that is proceeding.
The merged company could have $60 million cash and a cashcow in its diagostic test as clinical development is now behind it and it is expected to be relicensed.
According to an article Novo Nordisk, which is now the largest company in Europe by market cap, plunked down the following for AEZS's growth hormone deficiency diagnostic test:
...US$145 million plus tiered royalties and an equity investment worth more than US$36 million...
That's close to C$250 million in cash and equity plus tiered royalties.